Emerge Weight Loss vs Hers
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Emerge Weight Loss
Best for patients committed to tirzepatide as their drug of choiceStarting at $299/mo
Hers
Best for mainstream telehealth GLP-1 accessStarting at $199/mo
Side-by-Side Comparison
| Feature | Emerge Weight Loss | Hers |
|---|---|---|
| Overall Score | ✓7.6/10 | 7.4/10 |
| Starting Price | $299/mo | ✓$199/mo |
| Customer Rating | — | — |
| Features | ✓4 features | 2 features |
| States Available | 50 | 50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Emerge Weight Loss
Pros
- ✓Tirzepatide-focused (largest effect-size compounded GLP-1)
- ✓Wide dose range available
- ✓Physician-supervised telemedicine model
Cons
- ✗No semaglutide option — limits flexibility if tirzepatide tolerability is poor
- ✗Less brand recognition than Henry Meds, Mochi, or SkinnyRx
Hers
Pros
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
Our Verdict
Emerge Weight Loss edges out Hers with a higher overall score of 7.6/10 and is particularly strong for patients committed to tirzepatide as their drug of choice. Hers remains a solid alternative, especially if you're looking for mainstream telehealth GLP-1 access.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.